Price movement over the last 24 hours
Acadia Healthcare Company Inc vs Heron Therapeutics Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.8 (market cap $2.94B), while Heron Therapeutics Inc trades at $0.43 (market cap $80.58M). The key difference: Acadia Healthcare Company Inc is far larger — about 36.5× Heron Therapeutics Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | HRTX | |
|---|---|---|
Market Cap | $2.94B | $80.58M |
Sector | Health | Health |
52-Week High | $31.92 | $2.23 |
52-Week Low | $11.68 | $0.39 |
Enterprise Value | $5.45B | $178.48M |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
HRTX trades at $0.4339, down 1.03% today, with neutral technical signals and mixed earnings performance. The company reported a Q1 2026 loss of $0.04 per share, missing estimates, but maintains a strong gross margin of 71.12% and a low P/S ratio of 0.47. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite quarterly pressures.
Outlook remains speculative given persistent net losses and negative cash flow from operations, though analyst consensus is overwhelmingly bullish with 94.74% buy ratings. Key risks include execution challenges and competitive threats in the biotechnology sector, while potential upside hinges on achieving profitability and successful product commercialization.
Trailing returns across standard periods
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →